CN1095713A - 制造某些硫醚的方法 - Google Patents
制造某些硫醚的方法 Download PDFInfo
- Publication number
- CN1095713A CN1095713A CN93109433A CN93109433A CN1095713A CN 1095713 A CN1095713 A CN 1095713A CN 93109433 A CN93109433 A CN 93109433A CN 93109433 A CN93109433 A CN 93109433A CN 1095713 A CN1095713 A CN 1095713A
- Authority
- CN
- China
- Prior art keywords
- group
- phenyl
- lower alkoxy
- low alkyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及一种制造通式I的化合物的方法。
其中在此定义了一些基团,该方法包括在DBU
存在下,在惰性气氛中使苯硫酚或苯基烷基硫醇偶
合。这些化合物是白细胞三烯的对抗物,因此可用于
治疗与白细胞(leukotrienes)有关的各种疾病。
Description
本发明的领域是通过使氯甲基吡啶基化合物与苯硫酚及相关的硫醇偶合来制造某些硫醚的方法。这种偶合的产物,硫醚及其相关的亚砜和砜可用于治疗由白细胞三烯(leukotrienes),特别是白细胞三烯B4(leukotriene B4)引起的或者与其有关的疾病。因此其用途是抵抗白细胞三烯的感染。
已经发现一系列用下述通式代表的硫醚可用于治疗包括白细胞三烯链(leukotriene cascade),特别是认为与二羟基白细胞三烯(白细胞三烯B4)有关或由其引起的疾病:
这些硫醚可在某些出版物,特别是PCT申请登记号为PCT/US91/03772中找到。其中公开了制备那些新型治疗药剂的方法,并描述了生物活性类脂类(已知的如白细胞三烯)族的应用及背景。
本发明涉及一种制造这些化合物和其他具有相似性质的化合物的方法,其中使氯甲基吡啶与苯硫酚或苄基硫醇相偶合。
本发明覆盖一种制造通式Ⅰ
的化合物的方法,其中R1包含一个α,β-不饱和羰基,符号(R)n表示氢或一个或多个能够在吡啶环和苯环上形成共价键的非氢基团,m是0-5;该方法包括在1,8-二氮双杂环[5.4.0]十一碳-7-烯(DBU)的存在下,在惰性气体和介于约室温-100℃之间的温度下使通式Ⅱ的氯甲基吡啶与通式Ⅲ的硫醇在足以产生偶合的一段时间内偶合。
其中R1是如上所定义,(R)n是氢一个或多个或者可在吡啶环上或者可在苯环上被取代的基团,m是0-5。
下列定义用于说明本发明。
α,β-不饱和羰基是用-CH=CH-C(=O)-或-C≡C-C(=O)-来表示的。未定义的羰基官能价键可以是碳-碳键,碳-杂原子键,其中杂原子是氧、氮、硫或诸如此类,包括磷。本发明试图包括所有可能发生的情况,其中上述类型的硫醇与在2-位有一个α,β-不饱和羰基体系的吡啶基衍生物发生反应,其中在2-位上可以与硫醇发生米歇尔(Michael)加成反应。
(R)n符号在这里用于表示或者可在吡啶环上或者可在苯环上存在一个或多个基团。本发明还包括这些R基团中的每一个都是氢的情况。可以预计到任何数目的基团及取代基的结合都可以在两种环中的任何一种上存在。可以预计到的唯一限制是这些基团之一必须不干扰偶合反应以致于到反应不能实现的程度,即,反应根本不发生,产量小到趋于零,得到了较多的非所需产物。应当明白所给基团可以以被保护的形式存在,例如羧化物官能团可以以酯的形式存在,该酸在偶合反应一完成就通过水解,催化或酶催化的方法再生出来。本发明是采用DBU使氯和硫醇产生偶合以获得硫醚,并且认为只能这样限定。
至于其他术语,“脂肪族”的希望包括饱和和不饱和基团。这包括直链和支链,饱和链或单或多不饱和链,其中双键和三键都可以以任意结合的形式存在。短语“低级烷基”表示以任意异构形式存在的含1-6个碳原子的烷基,但特别是以直的或线性的形式存在。“低级烷氧基”表示低级烷基-O-基。“酰基-低级烷基”指(O)C-低级烷基,其中羰基碳原子被认为是在低级烷基定义下所指出的1-6个碳原子中的一个。“卤代”指氟代、氯代、溴代或碘代。苯环可以被这些基团中的一个或多个取代。多个取代基可以相同或不同,例如其中有三个氯,或是氯与烷基和其他基团的结合,其中后者的结合可以在氯/烷基类型中有不同烷基。
吡啶环氮的氧化物可以通过现有技术已知的和在此阐述的方法来制备。这些也将被认为是本发明的一部分。
如果通过取代基的一些结合,在本发明的化合物中形成了一个手性中心或形成了另一种形式的异构中心,则所有这些形式的异构体都希望被包括在本文。具有手性中心的化合物可以作为外消旋的混合物来处理,或者分离外消旋体并单独使用单个对映体。
化合物1,8-二氮双杂环[5,4,0]十一碳-7-烯(DBU)可以从Aldrich得到。为了产生偶合,硫醇溶解在无水极性溶剂如乙腈中,加入约一当量将被偶合的氯甲基吡啶加合物。然后加入用硫醇来计量的2-5当量之间的DBU,优选3当量的DBU。在开始和进行反应的过程中保持无水条件。采用惰性气氛,优选氩气。反应是在大约室温-100℃之间搅拌几小时。通过在氩气氛和约50℃的温度下加热被搅拌的反应物2-4小时,可以使反应以有利的方式进行。随后,冷却反应,回收并且用常规方法提纯产物硫醚。
本发明的优选产物是那些通式ⅠA的化合物
或一种N-氧化物,或一种药理上可接受的盐,其中m是0-5;
R是C1至C20-脂族基,未取代的或取代的苯基-C1至C10-脂族基,其中取代苯基带一个或多个选自由低级烷氧基,低级烷基,三卤代甲基,和卤素所组成的一组的基团,或R是C1至C20脂族基-O-,或R是未取代的或取代的苯基-C1至C10脂族基-O-其中取代苯基带一个或多个选自由低级烷氧基,低级烷基,三卤代甲基,和卤素所组成的一组的基团;
R1是-(CH2)xCH=CHCORy,或-(CH2)xCH=CHCHO,其中X是0-2,Ry是-OH或它的酯或NH2或它的取代酰胺衍生物;
R2是H,低级烷氧基,卤素,-CN,-(CH2)nR4(其中n是0-5),低级烷基,或CF3;
R3是H,低级烷氧基,卤素,低级烷基,CF3-CN,-(CH2)nR4(其中n是0-5);
R4是四唑-5-基或COR5;和
R5是低级烷氧基,CH3(CH2)0-6CO或苯基(CH2)0-3CO。
更优选的产物是那些其中R是取代苯基-C2至C8烷氧基,特别是未取代的苯基(CH2)2-8-O-基团,或者对一氟代-或对一甲氧基苯基(CH2)2-8-O-基团,或是CH3(CH2)7-9-O-;m是0-5,最佳为0,1,或2;R1是HO2C-CH=CH-,或HO2C-CH2CH2-或它的盐,酯或酰胺衍生物。优选产物的另一族是那些其中R2和R3都是氢,都是卤素,都是甲基,或都是甲氧基。另一组优选的化合物是那些其中R2是COR5且R3是氢。2,6-二氯代物是优选产物。特别优选的产物是:
(E)-甲基3-[3-[4-(4-甲氧基苯基)丁氧基]-6-[(2,6-二氯代苯基硫代)甲基]-2-吡啶基]-2-丙烯酸酯,
(E)-甲基3-[3-[4-(4-甲氧基苯基)丁氧基]-6-[苯基硫代甲基]-2-吡啶基]-2-丙烯酸酯,
(E)-甲基3-[3-[2-(4-甲氧基苯基)乙氧基]-6-[(2,6-二氯代苯基硫代)-甲基]-2-吡啶基]-2-丙烯酸酯,
(E)-甲基3-[3-[2-(4-氟代苯基)乙氧基]-6-[(2,6-二氯代苯基硫代)甲基]-2-吡啶基]-2-丙烯酸酯,或
(E)-甲基3-[3-[8-(4-甲氧基苯基)辛氧基]-6-[(3-甲氧羰基-苄基硫代)甲基]-2-吡啶基]-2-丙烯酸。
合成
采用了几种在同一工艺上加以变化的方法来制备这些化合物。一般来说,采用的方法首先要制备形成R基所需要的中间体,然后要制备形成通式Ⅰ的核心结构所需要的苯基中间体;然后制备了吡啶基中间体并与苯基中间体反应形成核心结构。然后制备了盐,游离酸,酰胺,交替酯和诸如此类的物质。
如上所述,第一步要制备形成那些R基所需要的中间体,该中间体在市场上买不到。这种化学原理是为了说明取代苯基-C1至C10-脂族基-O-基的情况。相同或相似化学原理已在出版的专利申请,例如PCT国际申请号PCT/US91/03772,PCT/US91/03940,和PCT/US91/03399中公开了。在这些文件中建立的化学原理可替代或连同这里所给的化学原理用于制备通式Ⅰ的R基。
通常下一步就制备取代的氯甲基吡啶,与硫醇中间体相反,但这并不是实现本发明的关键。制备取代的6-氯甲基吡啶基中间体可以从初始化合物开始,而且在PCT申请PCT/US91/03772和上面引用的其他PCT案件中公开了化学原理。在′033772案件中建立的化学原理可用于将初始物料,2,6-二甲基吡啶-α2,3-二醇,转变成,例如2-(E-2-羧甲基乙烯基)-3-[4-(4-甲氧基苯基)丁氧基]-6-氯甲基吡啶。这里可用下面所给的图Ⅰ来说明。然后,用新的化学原理,包括条件和试剂DBU,使苯硫酚和氯甲基取代的吡啶偶合以制备通式Ⅰ的基本结构。然后如果需要的话,用碱或酸使酯基水解。通过把盐的溶液酸化可从盐得到游离酸。用标准反应条件和试剂可制备酯和酰胺。从相应酸的卤化物,例如酸的氯化物,用文献方法制备了四唑。可以采用按照每个上述PCT申请来制备的产物母体或从商业渠道购买的产物母体,以及图Ⅰ所概括的步骤,来制备通式Ⅰ的化合物。
图Ⅰ
用于把二元醇转化成6-(氯甲基)吡啶化合物的条件和试剂的一般说明可在PCT申请号PCT/US91/03772中找到。该被概括案件的每一步的描述连同在那份申请的实施例中建立的特定化学原理被引入本文作参考。
许多可用于制备通式Ⅰ的右手部分的苯硫酚和硫代烷基苯基化合物可从商业渠道购买。一个并不打算详尽列举的表如下:2,5-二氯代苯硫酚,2,6-二甲基苯硫酚,2-氯-6-氟代苄基硫醇,和2,4-二氟代苄基硫醇。其他硫醇可通过公开的化学原理制备;该化学原理包括通过用硫脲处理溴代化合物并随后碱性水解把卤代烷基苯基(优选溴化形式)化合物转化成相应的硫醇。另一种方法是通过相应的硫代氨基甲酸酯的热重排并随后水解来制备苯硫酚。
用一种采用1,8-二氮双杂环[5,4,0]十碳-7-烯(DBU)和适当的溶剂(例如CH3CN)的新方法使硫醇和氯甲基吡啶基化合物偶合。从体系中排除水分并采用惰性气体,例如氩气。优选稍微升高温度至大约50℃左右;偶合反应在3小时内完成。
一旦制成了核心结构,则任何酯就可以用酸或碱水解,优选用碱,或者那种酸可被转化成另一种酯、酰胺或另一种盐。
下面给出实施例以说明怎样制备和使用本发明的化合物,这些实施例只是例子,并不希望约束或换句话说限定本发明的范围。它们作为权利要求的参考以定义保留给出发明人的权利。
实施例1
(E)-锂3-[3-[4-(4-甲氧基苯基)丁氧基]-6-[(2,6-二氯代苯基硫代)甲基]-2-吡啶基]-2-丙烯酸酯
2A(E)-甲基3-[3-[4-(4-甲氧基苯基)丁氧基]-6-[(2,6-二氯代苯基硫代)甲基-2-吡啶基]-2-丙烯酸酯。2,6-二氯代苯硫酚(53毫克,0.297毫摩尔、Aldrich)溶解在无水MeCN(0.60毫升)中,并用2-(E-2-羧甲基乙烯基)-3-[4-(4-甲氧基苯基)丁氧基]-6-氯甲基吡啶盐酸化物(115毫克,0.270毫摩尔)和1,8-二氮双杂环[5,4,0]十一碳-7-烯(DBU,0.142毫升,0.949毫摩尔)。反应在氩气和50℃下搅拌3小时。反应溶液用EtOAc稀释,用水和盐水洗涤,并干燥(MgSO4)。通过快速柱色谱法(二氧化硅,EtOAc∶CH2Cl2∶己烷,10∶15∶75)提纯得到一种无色蜡状固体:1HNMR(250兆赫,CDCl3δ7.94(d,J=15.7赫兹,1H,乙烯基),7.11(d,J=8.4赫兹,1H,吡啶基),7.31(d,J=8.7赫兹,芳基),7.13(m,4H,芳基,吡啶基),6.86(d,J=8.7赫兹,2H,苯基),6.69(d,J=15.7赫兹,1H,乙烯基),4.14(s,2H,CH2-S),3.97(t,J=6.1赫兹,2H,CH2-O),3.80(s,3H,OMe),3.78(s,3H,甲酯),2.63(t,J=7.2赫兹,2H,苄基),1.81(m,4H,CH2CH2);对C27C27Cl2NO4S的分析,计算:C,60.90;H,5.11;N,2.63;实测:C,60.61;H,5.01;N,2.57;MS(ES+):532.0(M+H)。
按照相似的方法,但用适当的氯甲基吡啶和苯硫酚或巯基烷基苯基加合物代替1A和1B所列的中间体,可制得下列化合物。
(E)-甲苯3-[3-[8-(4-甲氧基苯基)辛氧基]-6-[(3-甲氧羰基苄基硫代)-甲基]-2-吡啶基]-2-丙烯酸酯,
(E)-甲基3-[3-[4-(4-甲氧基苯基)丁氧基]-6-[苯基硫代甲基]-2-吡啶基]-2-丙烯酸酯,和
(E)-甲基3-[3-[4-(4-甲氧基苯基)丁氧基]-6-[(2,6-二氯代苯基硫代)甲基]-2-吡啶基]-2-丙烯酸酯。
2B(E)-锂3-[3-[4-(4-甲氧基苯基)丁氧基]-6-[(2,6-二氯代苯基硫代)甲基]-2-吡啶基]-2-丙烯酸酯。(E)-甲基3-[3-[4-(4-甲氧基苯基)丁氧基]-6-[(2,6-二氯代苯基硫代)甲基-2-吡啶基]-2-丙烯酸酯(65毫克,0.122毫摩尔)溶解在THF(1.0毫升)和MeOH(0.50毫升)中并用1.0M LiOH(0.25毫升,0.25毫摩尔)处理。反应在氩气下拌20小时,蒸发掉溶剂并把产物用反相MPLC(RP-18二氧化硅,H2O-MeOH梯度)提纯。低压升华干燥法产生了一种无色非晶体形固体:1HNMR(250兆赫,d4-MeOH)δ7.68(d,J=15.7赫兹,1H,乙烯基),7.37(d,J=7.6赫兹,2H,芳基),7.13(m,4H,芳基,吡啶基),7.02(d,J=8.4赫兹,1H,吡啶基),6.82(d,J=15.7赫兹,1H,乙烯基),6.81(d,J=8.7赫兹,2H,苯基),4.13(s,2H,CH2-S),4.00(t,J=6.1赫兹,2H,CH2-O),3.75(s,3H,OMe),2.62(t,J=7.2赫兹,2H,苄基),1.80(m,4H,CH2CH2);对C26H24Cl2NO4SLi·15/8H2O的分析,计算:C,55.95;H,5.01;N,2.51;实测:C,55.75;H,4.58;N,2.36;MS(ES+):518.0(M+H,游离酸)。
Claims (3)
2、权利要求1的方法,其中采用了3当量的DBU,反应是在氩气下于约50℃的温度在乙腈中进行了2-4小时。
3、权利要求2的方法,其中产物是通式IA的化合物
或一种N-氧化物,或一种药理上可接受的盐,其中
R是C1至C20一脂族基,其中取代的或未取代的苯基-C1至C10-脂族基,其中取代苯基带一个或多个选自由低级烷氧基,低级烷基,三卤代甲基,和卤素所组成的一组的基团,或R是C1至C20-脂族基-O-,或R是未取代的或取代的苯基-C1至C10脂族基-O-,其中取代苯基带一个或多个选自由低级烷氧基,低级烷基,三卤代甲基,和卤素所组成的一组的基团;
R1是-(CH2)xCH=CHCORy,或-(CH2)xCH=CHCHO,其中X是0-2,Ry上-OH或它的酯或NH2或它的取代酰胺衍生物;
R2是H,低级烷氧基,卤素,-CN,-(CH2)nR4(其中n是0-5),低级烷基,或CF3;
R3是H,低级烷氧基,卤素,低级烷基,CF3-CN,-(CH2)nR4(其中n是0-5),
R4是四唑-5-基或COR5;和
R5是低级烷氧基,CH3(CH2)0-6CO或苯基(CH2)0-3CO。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90695192A | 1992-06-30 | 1992-06-30 | |
US906,951 | 1992-06-30 | ||
US2520093A | 1993-03-02 | 1993-03-02 | |
US025,200 | 1993-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1095713A true CN1095713A (zh) | 1994-11-30 |
Family
ID=26699426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN93109433A Pending CN1095713A (zh) | 1992-06-30 | 1993-06-30 | 制造某些硫醚的方法 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0649408A4 (zh) |
JP (1) | JP3181917B2 (zh) |
KR (1) | KR950702184A (zh) |
CN (1) | CN1095713A (zh) |
AU (1) | AU678979B2 (zh) |
CA (1) | CA2138955A1 (zh) |
MX (1) | MX9303972A (zh) |
NZ (1) | NZ254473A (zh) |
TW (1) | TW247907B (zh) |
WO (1) | WO1994000433A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1314666C (zh) * | 2005-12-19 | 2007-05-09 | 华中师范大学 | 微波辅助合成硫醚类化合物的方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09506367A (ja) * | 1993-12-08 | 1997-06-24 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
GB9508137D0 (en) * | 1995-04-21 | 1995-06-07 | Smithkline Beecham Plc | Formulation |
KR200481393Y1 (ko) * | 2014-08-06 | 2016-09-27 | 김상열 | 스마트 슬림 스탠드 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3810379A1 (de) * | 1988-03-26 | 1989-10-12 | Hoechst Ag | Azaneophyl- und silazaneophylsulfide, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als schaedlingsbekaempfungsmittel |
WO1991018601A1 (en) * | 1990-06-07 | 1991-12-12 | Smithkline Beecham Corporation | Benzoic acid derivatives |
CA2089728A1 (en) * | 1990-09-13 | 1992-03-14 | James S. Frazee | Pyridylthio or pyridyloxy alkanoic acids |
AU2573592A (en) * | 1991-09-19 | 1993-04-27 | Smithkline Beecham Corporation | Pyridine compounds for treating leukotriene-related diseases |
-
1993
- 1993-06-30 CN CN93109433A patent/CN1095713A/zh active Pending
- 1993-06-30 MX MX9303972A patent/MX9303972A/es unknown
- 1993-06-30 WO PCT/US1993/006177 patent/WO1994000433A1/en not_active Application Discontinuation
- 1993-06-30 CA CA002138955A patent/CA2138955A1/en not_active Abandoned
- 1993-06-30 NZ NZ254473A patent/NZ254473A/en unknown
- 1993-06-30 JP JP50263894A patent/JP3181917B2/ja not_active Expired - Lifetime
- 1993-06-30 AU AU46557/93A patent/AU678979B2/en not_active Ceased
- 1993-06-30 EP EP93916841A patent/EP0649408A4/en not_active Withdrawn
- 1993-07-27 TW TW082105973A patent/TW247907B/zh active
-
1994
- 1994-12-24 KR KR1019940704738A patent/KR950702184A/ko not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1314666C (zh) * | 2005-12-19 | 2007-05-09 | 华中师范大学 | 微波辅助合成硫醚类化合物的方法 |
Also Published As
Publication number | Publication date |
---|---|
MX9303972A (es) | 1994-04-29 |
JP3181917B2 (ja) | 2001-07-03 |
EP0649408A4 (en) | 1995-06-21 |
AU678979B2 (en) | 1997-06-19 |
WO1994000433A1 (en) | 1994-01-06 |
TW247907B (zh) | 1995-05-21 |
AU4655793A (en) | 1994-01-24 |
CA2138955A1 (en) | 1994-01-06 |
KR950702184A (ko) | 1995-06-19 |
NZ254473A (en) | 1996-11-26 |
EP0649408A1 (en) | 1995-04-26 |
JPH07508283A (ja) | 1995-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS55102583A (en) | 20-acyloxy-20-demethylmaytansinoid compound | |
EP0325130A2 (de) | Substituierte Pyridine | |
CH653989A5 (de) | Cyclobutendion-verbindungen. | |
CN1095713A (zh) | 制造某些硫醚的方法 | |
ES2182211T3 (es) | Proceso para la fabricacion de compuestos de bis(oxido de fosfina) y bis(fosfonato). | |
DE69317704D1 (de) | Trialkylzinn-Verbindungen mit höheren Alkylgruppen und deren Verwendung | |
ATE221890T1 (de) | Verfahren zur selektiven herstellung von z- isomeren von 3-(2-substituiertes vinyl)cephalosporinen | |
US4355034A (en) | Ethenyl derivatives of mercaptoalkylpyridines as anti-inflammatory agents | |
EP0556680B1 (de) | Verfahren zur Herstellung von Benzo[b]thiophenen | |
US5700943A (en) | Process for making phenylthiomethylpyridinylalkenoates | |
US4177274A (en) | Substituted imidazo [1,2-a] pyridines | |
DE2709504C3 (zh) | ||
EP0187674A2 (en) | Process for the preparation of polyhalogenated carbinols | |
DE3121510A1 (de) | 6-alkyl-2-subst.-peneme und verfahren zu ihrer herstellung | |
JPS6061575A (ja) | 複素環式化合物の製法 | |
DE60006311D1 (de) | Phosphinoxid-Vitamin D Vorläufer | |
WO2002085516A1 (fr) | Catalyseur complexe, son procede de production, et procede de production d'un derive d'alcool faisant appel a ce catalyseur complexe | |
EP0196276B1 (de) | Verfahren zur Herstellung von teilhalogenierten 1-Propanolen | |
DE2919891A1 (de) | Substituierte 4-amino-2-aza-1,3- butadiene, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von heterocyclischen verbindungen | |
DE3123864A1 (de) | Verfahren zur herstellung von 3-(n-aryl-n-acylamino)-(gamma)-butyrothiolaten | |
EP0916656A3 (en) | A method for production of pyrrolidinone derivatives | |
JPH03862B2 (zh) | ||
US4144342A (en) | 2-Methyl-3-hydroxy-4-alkanoylthiomethyl-5-vinylpyridines | |
DE59913953D1 (de) | Verfahren zur Herstellung von Phenoxypropinsäurepropargylestern | |
KR20020031981A (ko) | 2-머캡토피리딘 n-옥사이드 유도체의 신규한 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |